Company: INDP
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001641172-25-005234
Chunk: 24

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 24
---
 this range as determined by our Board of Directors in its sole discretion, any time prior to the close of business on June 10, 2026. We believe that enabling our Board of Directors to set the ratio within the stated Range will provide us with the flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for our stockholders. In determining a ratio, if any, our Board of Directors may consider, among other things, factors such as:

| ● | the                                                                                                                               
 initial or continuing listing requirements of various stock exchanges, including the Nasdaq Capital Market;                       |
| ● | the                                                                                                                               
 historical trading price and trading volume of our common stock;                                                                  |
| ● | the                                                                                                                               
 number of shares of our common stock outstanding;                                                                                 |
| ● | the                                                                                                                               
 then-prevailing trading price and trading volume of our common stock and the anticipated impact of the Reverse Stock Split on the 
 trading market for our common stock;                                                                                              |
| ● | the                                                                                                                               
 anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs; and                     |
| ● | prevailing                                                                                                                        
 general market and economic conditions.                                                                                           |

Our Board of Directors reserves the right to elect to abandon the Reverse Stock Split, including any proposed reverse stock split ratio, if it determines, in its sole discretion, that the Reverse Stock Split is no longer in the best interests of the Company and its stockholders.

| 14 |

Depending on the ratio for the Reverse Stock Split determined by our Board of Directors, no less than 5 and no more than 28 shares of existing common stock, as determined by our Board of Directors, will be combined into one share of common stock. Any fractional shares that would otherwise be issuable as a result of the Reverse Stock Split will be paid out in cash. The amendment to our Restated Certificate to effect a Reverse Stock Split, if any, will include only the reverse split ratio determined by our Board of Directors to be in the best interests of our stockholders and all of the other proposed amendments at different ratios will be abandoned.

Reasons for the Reverse Stock Split; Potential Consequences of the Reverse Stock Split

Our primary reasons for approving and recommending the Reverse Stock Split are to increase the per share price and bid price of our common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base.

On January 31, 2025